OptimizeRx Corporation reported second quarter 2026 financial results with revenue of $20.5 million, a 30% decrease from the prior year period, and a GAAP net loss of $(0.7) million. The company reaffirmed its full-year 2026 guidance for revenue between $95 million and $100 million and adjusted EBITDA between $21 million and $25 million. Concurrently, the Board approved a finance leadership succession plan effective January 1, 2027. Edward Stelmakh will step down as Chief Financial & Strategy Officer on December 31, 2026, receiving severance including 12 months of salary continuation totaling $450,000 and a one-time bonus payment of $247,500. Andrew D’Silva is appointed as the new Chief Financial Officer with an annual base salary of $375,000, and Heather Favazza is appointed as Chief Accounting Officer with an annual base salary of $325,000. OptimizeRx operates in the healthcare technology industry, providing AI-driven audience intelligence and programmatic engagement solutions for life sciences companies to connect with healthcare professionals and patients.

At its 2026 Annual Meeting of Shareholders held on June 9, 2026, OptimizeRx Corporation shareholders approved an amendment to the 2021 Equity Incentive Plan to increase the available common stock for awards by 1,000,000 shares, bringing the total to 5,450,000 shares. Shareholders also elected seven directors, approved advisory executive compensation, and ratified Grant Thornton, LLP as the independent auditor for the 2026 fiscal year. However, a proposal to adopt an evergreen provision for automatic annual increases to the Equity Plan was rejected. OptimizeRx Corporation is a healthcare technology company providing commercialization solutions.